Correction: Prescribing Cascades with Recommendations to Prevent or Reverse Them: A Systematic Review (vol 40, pg 1085, 2023)

In the sentence beginning ‘Explicit recommendations regarding alternative options…’ in the Abstract section of this article, the term ‘for three prescribing cascades’ should have read ‘for five prescribing cascades.’ The complete sentence should read: ‘Explicit recommendations regarding alternative options were given for five prescribing cascades.’ In the sentence beginning ‘For 22 prescribing cascades, …’ the text ‘but only for three it was mentioned to which medication (Table 2)’ should have read ‘but only for five it was mentioned to which medication (Table 2).’ The complete sentence should read: ‘For 22 prescribing cascades, recommendations were made to switch the index medication but only for five it was mentioned to which medication (Table 2).’ The following sentence, which previously read: ‘Kirwan et al. [72] recommended the switch to betaxolol when an obstructive airways disorder is experienced when using antiglaucoma preparations, whereas Avorn et al. [71] recommended to switch to any other antiglaucoma preparation.’ should read ‘Avorn et al [71] recommended to switch to beta-1-selective agents when an obstructive airways disorder is experienced when using nonselective beta-blockers for glaucoma.’ In Table 2, ‘Prescribing cascade’ section, ‘Cardiovascular system’ subsections, ‘ACE-inhibitors, including combinations (C09A, C09B)’ and ‘ACE-inhibitors (C09AA)’ row: The cell entry in column 6, which previously read: “DL [26]” and “DL [28]” should be deleted. In the same subsection, ‘Atorvastatin’ row: The cell entry in column 6, which previously read: ‘SW [31]’ should read ‘SW (fluvastatin, lovastatin, pravastatin, rosuvastatin) [31].’ In the ‘Dihydropyridines (C08CA)’ row of the same subsection: The cell entry in column 6, which was previously empty should read ‘DIS, DL, SW [39].’ In the ‘Amlodipine, nifedipine, felodipine**’ row: The cell entry in column 6, which was previously empty should read ‘DL, DIS [41].’ Under the ‘Musculo-skeletal system (M)’ subsection, ‘Miscellaneous NSAIDs (within M01A)’ row: The cell entry in column 6, which previously read: ‘DIS, DL, SW [52]’ should read ‘DIS, DL, SW (acetaminophen) [52]’. In the ‘Sensory organs (S)’ subsection, ‘Antiglaucoma preparations and miotics (S01E)’ row: The cell entry in column 6, which previously read: ‘SW (betaxolol) [71, 72]’ should read ‘SW (beta-1-selective agents) [71].’ And the cell entries in column 6, which previously read: ‘SW [71, 72]’ and ‘DIS [73]’ should be deleted. The incorrect and correct versions of Table 2 are given below. Incorrect version of Table 2: Table 2 Prescribing cascades with at least one positive significant association between the index and marker medication, with confirmed ADRs and a dose-dependency analysis and/or recommendations to prevent or reverse the prescribing cascade Prescribing cascade analyses ^a Dose-dependency analysis ^b O = Other ^c O = Other ^c 1. Metoclopramide (A03FA01) Extrapyramidal syndrome (10015836) Anti-parkinson drugs (N04) +R [21, 22] +R [21] SW (ondansetron or granisetron) [21] 2.